[The role of immunocorrective therapy in the combined treatment of rhinosinusitis].
The objective of the present work was to substantiate rational pharmacotherapy allowing not only to affect the pathogen but also to restore the initial state of the compromised immune system of the patient. This paper is focused on the markers of the immunodeficiency state in the patients presenting with acute and chronic bacterial rhinosinusitis taking into consideration the nature of the pathogen. A rationale is presented for the management of this pathology with the use of the natural topical immunostimulator IRS-19 that can be recommended for the introduction into combined therapy of acute and chronic rhinosinusitis for the achievement of well-apparent and stable results.